A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults
NCT ID: NCT06890416
Last Updated: 2025-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
526 participants
INTERVENTIONAL
2025-04-04
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Coadministration Group
* Visit 1 (Day 1): RSVpreF + HZ/su dose 1
* Visit 3 (Month 2): HZ/su dose 2
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE
Intramuscular injection
HZ/su VACCINE
intramuscular injection
Sequential Administration Group
* Visit 1 (Day 1): HZ/su dose 1
* Visit 2 (Month 1): RSVpreF
* Visit 3 (Month 2): HZ/su dose 2
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE
Intramuscular injection
HZ/su VACCINE
intramuscular injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE
Intramuscular injection
HZ/su VACCINE
intramuscular injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Prior history of any subtype of Guillain Barré syndrome of any etiology.
* Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
* Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination, and medication list
* Previous vaccination with any licensed or investigational RSV vaccine at any time prior to enrollment, or planned receipt of a nonstudy RSV vaccine during study participation.
* Previous vaccination with any licensed recombinant adjuvant zoster vaccine (Shingrix) at any time prior to enrollment, or planned receipt of a nonstudy licensed VZV vaccine (Shingrix) during study participation.
* History of previous vaccination with live HZ vaccine (Zostavax) in the last 2 years from enrollment, or planned receipt through study participation.
* Previous vaccination with any investigational VZV vaccine at any time prior to enrollment, or planned receipt of a nonstudy investigational VZV vaccine during study participation.
* Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, immunosuppressive monoclonal antibodies, systemic corticosteroids (defined as ≥20 mg/day of prednisone or equivalent for ≥14 days), eg, for cancer or an autoimmune disease, or radiotherapy, from 60 days before study intervention administration, or planned receipt throughout the study.
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Research Associates
Birmingham, Alabama, United States
Medical Affiliated Research Center
Huntsville, Alabama, United States
AMR Clinical
Mobile, Alabama, United States
Kaiser Permanente
Los Angeles, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Alliance for Multispecialty Research, LLC
Doral, Florida, United States
Proactive Clinical Research,LLC
Fort Lauderdale, Florida, United States
De La Cruz Research Center, LLC
Miami, Florida, United States
Centricity Research Columbus Georgia Multispecialty
Columbus, Georgia, United States
Clinical Research Atlanta
Stockbridge, Georgia, United States
Synexus Clinical Research US, Inc.
Chicago, Illinois, United States
Optimal Research
Peoria, Illinois, United States
DelRicht Research
New Orleans, Louisiana, United States
Jadestone Clinical Research
Silver Spring, Maryland, United States
Oakland Medical Research
Troy, Michigan, United States
Clinical Research Professionals
Chesterfield, Missouri, United States
IMA Clinical Research Warren
Warren Township, New Jersey, United States
NYU Langone Health
New York, New York, United States
Centricity Research Columbus Ohio Multispecialty
Columbus, Ohio, United States
DM Clinical Research - Philadelphia
Philadelphia, Pennsylvania, United States
Clinical Neuroscience Solutions Inc.
Memphis, Tennessee, United States
DM Clinical Research - Bellaire
Houston, Texas, United States
SMS Clinical Research
Mesquite, Texas, United States
IMA Clinical Research San Antonio
San Antonio, Texas, United States
DM Clinical Research - Sugar Land
Sugar Land, Texas, United States
Clinical Research Puerto Rico
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PISSARRO
Identifier Type: OTHER
Identifier Source: secondary_id
C3671058
Identifier Type: -
Identifier Source: org_study_id